This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
New Immuno-Oncology Solutions (NIOS): Aligning Stakeholders in the Biotech Industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacCase SM-1701-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €8.20
-
The F.B. Heron Foundation: 100 Percent for Mission - And Beyond
Ewald, Charles; Krauel Patel, Heidi; Foroughi, JaclynCase SGSB-SI140-EInnovation and ChangeIn late March 2017, Clara Miller, director and president of the F.B. Heron Foundation (“Heron”), a philanthropic institution focused on helping people help themselves out of poverty, sat down to put the finishing touches on her President’s Letter. In previous years, the letter included Miller’s lucid thoughts regarding major changes within the organization and advocated for movement toward a “philanthropic world”—a world in which “all sectors—pu...Starting at €8.20
-
New Immuno-Oncology Solutions (NIOS) - Teaching Note: Aligning stakeholders in the biotech industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacTeaching Note SMT-136-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €0.00